In recent years, many aptamer-conjugated gene drug models have been established, and extensive preclinical evaluations have confirmed their feasibility for tumor treatment, such as PSMA aptamer conjugated with Plk1 or Bcl2 siRNA for prostate cancer treatment 18, HER2 aptamer conjugated with Bcl2 siRNA and cisplatin for breast cancer treatment 133, MUC1 aptamer conjugated microRNA-29b for ovarian cancer treatment 134 et al. This evidence concerns the gene BCL2 and prostate cancer.